But, like Merck two weeks ago, GSK has failed to hit overall survival.
ApexOnco Front Page
Recent articles
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
But with Brukinsa and degraders looming, will fixed dosing make the difference?
Enzomenib might be the most promising agent so far, on a cross-trial basis.
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
